Latest total revenue for CANF: $410K, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Dec 2025
Trailing 12 months ending Dec 2025
As of the most recent data (December 2025), CANF shows a total revenue of $410K. That compares with $670K in the prior-year period — down 39.9% year over year. That is below the Healthcare sector average of $110B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, CANF's total revenue is now $410K (was $670K) — a 39.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Can-Fite Biopharma is outperforming or lagging.
The Healthcare sector average total revenue is about $110B. Can-Fite Biopharma is at $410K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how CANF stacks up against individual peers as well.
Tracking CANF's total revenue over time shows whether Can-Fite Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $410K That compares with $670K in the prior-year period — down 39.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total revenue page, Stockcircle has Can-Fite Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $410K) with ownership activity and broader fundamentals.